{"id":"atra-and-or-chemo-as-maintenance","safety":{"commonSideEffects":[{"rate":null,"effect":"Retinoid acid syndrome (RAS)"},{"rate":null,"effect":"Hepatotoxicity"},{"rate":null,"effect":"Hypertriglyceridemia"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Dry skin and mucous membranes"},{"rate":null,"effect":"Bone pain"}]},"_chembl":{"chemblId":"CHEMBL3508697","moleculeType":"Small molecule"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"ATRA binds to retinoic acid receptors (RARα) and causes degradation of the PML-RARA fusion protein characteristic of acute promyelocytic leukemia (APL), forcing leukemic cells to differentiate into mature granulocytes rather than proliferate. When combined with chemotherapy as maintenance therapy, this approach reduces relapse risk by eliminating residual disease and maintaining long-term disease control in APL patients.","oneSentence":"ATRA (all-trans retinoic acid) induces differentiation of leukemic promyelocytes and promotes their maturation, often combined with chemotherapy to achieve complete remission in acute promyelocytic leukemia.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:02:59.766Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute promyelocytic leukemia (APL) — maintenance therapy"}]},"trialDetails":[{"nctId":"NCT07355855","phase":"PHASE2","title":"A Clinical Study on the Efficacy and Safety of All-trans Retinoic Acid Combined With VAC Regimen in the Treatment of Intermediate-to-high-risk Rhabdomyosarcoma","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2026-01","conditions":"Rhabdomyosarcoma","enrollment":106},{"nctId":"NCT00392327","phase":"PHASE3","title":"Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma/PNET","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2007-05-23","conditions":"Anaplastic Medulloblastoma, Medulloblastoma","enrollment":379},{"nctId":"NCT01526603","phase":"NA","title":"High Dose Chemotherapy and Autologous Transplant for Neuroblastoma","status":"COMPLETED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2012-03-28","conditions":"Neuroblastoma","enrollment":13},{"nctId":"NCT00492856","phase":"PHASE3","title":"S0521, Combination Chemotherapy With or Without Gemtuzumab Followed By Tretinoin, Mercaptopurine, and Methotrexate or Observation in Treating Patients With Acute Promyelocytic Leukemia","status":"COMPLETED","sponsor":"SWOG Cancer Research Network","startDate":"2007-06-01","conditions":"Leukemia","enrollment":105},{"nctId":"NCT00482833","phase":"PHASE3","title":"Phase III Trial in Acute Promyelocytic Leukemia Patients","status":"COMPLETED","sponsor":"Gruppo Italiano Malattie EMatologiche dell'Adulto","startDate":"2007-08","conditions":"Leukemia","enrollment":276},{"nctId":"NCT01987297","phase":"PHASE4","title":"Combined Retinoic Acid,Arsenic Trioxide and Chemo for Newly-diagnosed APL","status":"UNKNOWN","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2012-06","conditions":"Acute Promyelocytic Leukemia","enrollment":738},{"nctId":"NCT01067274","phase":"PHASE3","title":"ALFA-0703 Study in Older Patients With Acute Myeloblastic Leukemia (AML)","status":"WITHDRAWN","sponsor":"Acute Leukemia French Association","startDate":"2010-04","conditions":"Acute Myeloid Leukemia","enrollment":""},{"nctId":"NCT00003934","phase":"PHASE3","title":"Tretinoin, Cytarabine, and Daunorubicin Hydrochloride With or Without Arsenic Trioxide Followed by Tretinoin With or Without Mercaptopurine and Methotrexate in Treating Patients With Acute Promyelocytic Leukemia","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"1999-06","conditions":"Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Promyelocytic Leukemia (M3), Childhood Acute Promyelocytic Leukemia (M3)","enrollment":420},{"nctId":"NCT00599937","phase":"PHASE3","title":"APL93: Timing of CxT and Role of Maintenance","status":"COMPLETED","sponsor":"Groupe d'etude et de travail sur les leucemies aigues promyelocytaires","startDate":"1993-01","conditions":"Leukemia, Promyelocytic, Acute","enrollment":576}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":7630,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["ATRA"],"phase":"phase_3","status":"active","brandName":"ATRA and or Chemo as maintenance","genericName":"ATRA and or Chemo as maintenance","companyName":"Groupe d'etude et de travail sur les leucemies aigues promyelocytaires","companyId":"groupe-d-etude-et-de-travail-sur-les-leucemies-aigues-promyelocytaires","modality":"Small molecule","firstApprovalDate":"","aiSummary":"ATRA (all-trans retinoic acid) induces differentiation of leukemic promyelocytes and promotes their maturation, often combined with chemotherapy to achieve complete remission in acute promyelocytic leukemia. Used for Acute promyelocytic leukemia (APL) — maintenance therapy.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}